Analogs of Sodium Channel Peptide Toxin
AssigneePurdue Pharma L.P.
InventorsJae Hyun Park, Donald J. Kyle
Life of this patent
Estimating the term…
Abstract
The present invention relates to a peptide and analogs thereof that selectively inhibit the Nav1.7 sodium channel. The present invention also relates to pharmaceutical compositions useful for treating or preventing a disorder responsive to the blockade of sodium ion channels, especially Nav1.7 sodium ion channels. The present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly Nav1.7 sodium channels, in a mammal suffering from excess activity of said channels, compositions and methods for providing analgesia by administering a peptide of the invention.
Claims56
An isolated peptide comprising the amino acid sequence Tyr1-Cys2-Gln3-Lys4-Trp5-Met6-Trp7-Thr8-Cys9-Asp10-Ser11-Xaa12-Arg13-Lys14-Cys15-Cys16-Glu17-Gly18-Xaa19-Val20-Cys21-Arg22-Leu23-Trp24-Cys25-Lys26-Lys27-Xaa28-Xaa29-Xaa30-Xaa31 (SEQ ID NO:
- 1),
- or a pharmaceutically acceptable salt, prodrug or solvate thereof,
- wherein
- each of Xaa12, Xaa19, Xaa28 and Xaa29, is any natural or modified amino acid residue;
- Xaa30 is any natural or modified amino acid residue or is absent;
- and
- Xaa31 is any natural or modified amino acid residue or is absent,
- wherein said isolated peptide is not SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, or SEQ ID NO:
- 29,
- and wherein said isolated peptide is not ProTx II (SEQ ID NO:
- 16) or PaTx I (SEQ ID NO:
- 17).
(canceled)
(canceled)
Dependencies are inferred from the claim text.